More than Facebook Effect: Increasing opportunities for living kidney donation Save

Date Added
September 5th, 2017
PRO Number
Pro00065466
Researcher
Wendy Balliet
Keywords
Kidney, Transplant
Summary

Kidney transplant, especially from a living donor, affords End Stage Renal Disease (ESRD) patients the opportunity for increased survival and improved quality of life. Potential recipients are not likely to identify living donors as a believed consequence of lack of awareness and limited knowledge regarding living kidney donation. We propose to utilize a social media coach to help ESRD patients to utilize Facebook to tell their ESRD story, to post accurate information and links to data on ESRD, renal transplantation and living donation with the goal of increasing interest in social media 'friends' to become a living donor.

Institution
MUSC
Recruitment Contact
Thomas Morinelli
843-792-5405
morinelt@musc.edu

Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Save

Date Added
August 30th, 2017
PRO Number
Pro00066053
Researcher
Julie Kanter washko
Keywords
Transplant
Summary

This is a multi-center, longterm safety and efficacy follow-up study for subjects who have been treated with the LentiGlobin BB305 drug product on HGB-206 sickle cell gene therapy parent study. This study is observational only, and no investigational treatment will be given on this follow-up study. Participants for this study are requested to follow-up every six months for the first three years and then once every year for the remaining Year 4 through Year 13, totaling thirteen years in this longterm study. Study assessments will include exams, laboratory studies, imaging, ECG, surveys, and record review.

Institution
MUSC
Recruitment Contact
Brandi Day
843-792-3379
dayb@musc.edu

IMPROVING TRANSPLANT MEDICATION SAFETY THROUGH A PHARMACIST-EMPOWERED, PATIENT-CENTERED, MHEALTH-BASED INTERVENTION Save

Date Added
August 15th, 2017
PRO Number
Pro00068746
Researcher
David Taber
Keywords
Transplant
Summary

This is a medication safety study in kidney transplant recipients. Subjects will be provided with home monitoring devices and a mobile health application to improve medication safety.

Institution
MUSC
Recruitment Contact
Mackenzie Fraser
843-792-8896
fraserm@musc.edu

HLA-Matched Related Hematopoietic Stem Cell Transplantation for Children with Less Severe Sickle Cell Disease: a Sickle Transplantation Alliance for Research (STAR) Trial Save

Date Added
May 2nd, 2017
PRO Number
Pro00063146
Researcher
Jennifer Jaroscak
Keywords
Transplant
Summary

This study is being conducted to assess safety and efficacy of bone marrow transplant in less severely affected children. In this study, we will transplant bone marrow or cord blood from a HLA-matched brother or sister instead of the currently more common method with a HLA-identical sibling donor. This is a multicenter, single arm trial for patients between 2 and 10 years of age who have less severe HbSS or sickle beta zero thalassemia. Patient must have an HLA identical sibling donor who is less than 10 years old and who does not have HbSS, SC or sickle beta zero thalassemia.

Institution
MUSC
Recruitment Contact
Brandi Day
843-792-3379
dayb@musc.edu

Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection Save

Date Added
December 6th, 2016
PRO Number
Pro00060294
Researcher
Michelle Hudspeth
Keywords
Adolescents, Children's Health, Immune System, Lung, Pediatrics, Transplant
Summary

This study is for patient that have been diagnosed with suspected lower respiratory tract infection. The purpose of this study is to evaluate a new test that may be able to find more lung infections than current tests can. This new test is called next-generation sequencing and looks in respiratory secretions for bacteria, viruses, fungi, and other organisms that may cause infection. We hope to learn more about the usefulness of this new test in identifying infections.

Institution
MUSC
Recruitment Contact
Thomas Hortman
864-792-9579
hortman@musc.edu

A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease Save

Date Added
December 6th, 2016
PRO Number
Pro00056206
Researcher
Julie Kanter washko
Keywords
Blood Disorders, Transplant
Summary

This study is meant to compare transplant to standard care (regular care) for sickle cell patients. By comparing the health outcomes for patients who receive bone marrow transplant to those patients who receive standard of care, this study will be able to determine whether the two treatments are the same, or if one is better than the other.

Institution
MUSC
Recruitment Contact
Brandi Day
843-792-3379
dayb@musc.edu

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir. Save

Date Added
November 8th, 2016
PRO Number
Pro00058351
Researcher
Vinayak Rohan
Keywords
Drug Studies, Infectious Diseases, Transplant
Summary

This study is for patients who have received a kidney, liver, or pancreas transplant and who have developed resistant Cytomegalovirus infection. There will be two treatment groups to compare the improvement or resolution of Cytomegalovirus infection. Subjects will be randomized to receive 8 weeks of either the investigational drug, Maribavir, or physician assigned standard of care treatment.

Institution
MUSC
Recruitment Contact
Caitlin Schaffner
843-792-7558
schaffne@musc.edu

Advancing Treatment for Pancreatitis: A Prospective Observational Study of TPIAT (POST) Save

Date Added
August 16th, 2016
PRO Number
Pro00055080
Researcher
Katherine Morgan
Keywords
Diabetes, Digestive System, Insulin, Pancreas, Surgery, Transplant
Summary

The purpose of this research study is to learn more about the outcomes of total pancreatectomy with islet autotransplantation (TPIAT). Total pancreatectomy is the removal of the pancreas and islet autotransplantation is the placement of the insulin producing cells back into you to prevent diabetes. This study is looking to enroll patients who are scheduled to have a TPIAT surgery to treat pancreatitis (inflammation and scarring of the pancreas).

In addition to the routine care for pancreatitis and TPIAT surgery, participation in this study will involve completion of some brief surveys about the subject's health before TPIAT, at 6 months after TPIAT, and each year after the TPIAT surgery for 4 years, as well as a lab test conducted at each of the follow-up visits.

Institution
MUSC
Recruitment Contact
Christine Perez Rosa
843-792-0387
perezaro@musc.edu

ALFSG-MBT-003: 13C-Methacetin Breath Test for the Prediction of Outcome in Acute Liver Failure (ALF-MBT) Save

Date Added
May 17th, 2016
PRO Number
Pro00053899
Researcher
David Koch
Keywords
Liver, Transplant
Summary

This is an inpatient study to prove that the Methacetin Breath Test is a reliable tool to help doctors identify patients with acute liver failure who will or will not need a liver transplant.

Institution
MUSC
Recruitment Contact
Melanie Crolley
843-876-4273
crolley@musc.edu

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T cell replete Bone Marrow with post-transplantation cyclophosphamide for Children and Young Adults with Hematologic Malignancies Save

Date Added
May 3rd, 2016
PRO Number
Pro00054276
Researcher
Michelle Hudspeth
Keywords
Cancer, Cancer/Other, Men's Health, Transplant, Women's Health
Summary

This study is for participants who have been diagnosed with cancers of the blood who do not have a related perfect tissue ?match? for BMT. This research is being done to find out if a bone marrow transplant (BMT) from a relative who is not a perfect tissue match is safe and effective in people with cancer. The primary goal of this study is to use chemotherapy and/or radiation therapy to completely get rid of a person?s existing bone marrow, give them new bone marrow from a relative who is not a perfect tissue match, and then give them two doses of additional chemotherapy shortly after receiving the new bone marrow. Participants can expect to be in this study for up to 2 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login